New Jerseyan Insmed 'up for the rising' after US FDA lifts CF hold
This article was originally published in Scrip
Executive Summary
As if it had the power of fellow New Jerseyan Bruce Springsteen driving it on 7 May, biopharma Insmed was "up for the rising," with its shares soaring nearly 83% after the US FDA lifted the clinical hold it imposed last summer on the company’s programme for Arikace (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections.